The Company

SOTIO® is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. Our robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). We are building a pipeline of oncology programs by pursuing promising early stage candidates backed by strong science through strategic licensing, M&A and in-house discovery efforts. Our company has established the key capabilities required for research, preclinical and clinical development, commercial planning and market access, with the goal to rapidly advance the programs in our portfolio through clinical development towards commercialization.

SOTIO is developing the next generation of potent immunotherapies for patients with cancer. To achieve this goal, we intend to acquire therapeutic oncology assets that are at advanced preclinical or clinical stages to include in our portfolio. We are looking for differentiated drugs of varying modalities (small molecules, biologics, cell therapies, etc.) that have the potential to make a real difference in patients suffering from cancer. To date, SOTIO has established partnerships with Cytune Pharma (France) and NBE-Therapeutics (Switzerland). With these partnerships, SOTIO is responsible for preclinical and clinical development.

SOTIO has a geographic presence in Europe, the United States and China, enabling a global approach to clinical development. Our in-house GMP manufacturing facilities are located in Prague and Beijing. The Prague facility, one of the largest of its kind in Europe, supplies cell therapy products for clinical studies in both Europe and the United States. In Beijing, the facility supplies cell therapy products for research projects with leading Chinese hospitals.